- Home
- DTIL vs QNCX Comparison
DTIL vs QNCX Comparison
Compare DTIL & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- QNCX
- Stock Information
- Founded
- DTIL 2006
- QNCX 2012
- Country
- DTIL United States
- QNCX United States
- Employees
- DTIL N/A
- QNCX N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DTIL Health Care
- QNCX Health Care
- Exchange
- DTIL Nasdaq
- QNCX Nasdaq
- Market Cap
- DTIL 120.4M
- QNCX 139.2M
- IPO Year
- DTIL 2019
- QNCX 2019
- Fundamental
- Price
- DTIL $5.09
- QNCX $3.50
- Analyst Decision
- DTIL Strong Buy
- QNCX Strong Buy
- Analyst Count
- DTIL 2
- QNCX 4
- Target Price
- DTIL $47.00
- QNCX $7.75
- AVG Volume (30 Days)
- DTIL 251.8K
- QNCX 711.3K
- Earning Date
- DTIL 11-03-2025
- QNCX 11-12-2025
- Dividend Yield
- DTIL N/A
- QNCX N/A
- EPS Growth
- DTIL N/A
- QNCX N/A
- EPS
- DTIL N/A
- QNCX N/A
- Revenue
- DTIL $698,000.00
- QNCX N/A
- Revenue This Year
- DTIL N/A
- QNCX N/A
- Revenue Next Year
- DTIL $135.19
- QNCX N/A
- P/E Ratio
- DTIL N/A
- QNCX N/A
- Revenue Growth
- DTIL N/A
- QNCX N/A
- 52 Week Low
- DTIL $3.61
- QNCX $0.72
- 52 Week High
- DTIL $8.82
- QNCX $3.58
- Technical
- Relative Strength Index (RSI)
- DTIL 37.99
- QNCX 90.47
- Support Level
- DTIL $4.86
- QNCX $1.61
- Resistance Level
- DTIL $5.27
- QNCX $1.84
- Average True Range (ATR)
- DTIL 0.42
- QNCX 0.26
- MACD
- DTIL -0.14
- QNCX 0.16
- Stochastic Oscillator
- DTIL 23.58
- QNCX 96.26
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.